Abstract:Induction of broadly cross-reactive antiviral humoral responses with the capacity to target globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in the field is the identification of diverse HIV-1 envelope antigens to evaluate vaccine regimens for binding antibody breadth. In this study, we define unique antigen panels to map HIV-1 vaccine-elicited antibody breadth and durability. Diverse HIV-1 envelope glycoproteins were selected based on genetic and geographic diversity to cover the global epidemic, with a focus on sexually acquired transmitted/founder viruses with a tier 2 neutralization phenotype. Unique antigenicity was determined by nonredundancy (Spearman correlation), and antigens were clustered using partitioning around medoids (PAM) to identify antigen diversity. Cross-validation demonstrated that the PAM method was better than selection by reactivity and random selection. Analysis of vaccine-elicited V1V2 binding antibody in longitudinal samples from the RV144 clinical trial revealed the striking heterogeneity among individual vaccinees in maintaining durable responses. These data support the idea that a major goal for vaccine development is to improve antibody levels, breadth, and durability at the population level. Elucidating the level and durability of vaccine-elicited binding antibody breadth needed for protection is critical for the development of a globally efficacious HIV vaccine. IMPORTANCE The path toward an efficacious HIV-1 vaccine will require characterization of vaccine-induced immunity that can recognize and target the highly genetically diverse virus envelope glycoproteins. Antibodies that target the envelope glycoproteins, including diverse sequences within the first and second hypervariable regions (V1V2) of gp120, were identified as correlates of risk for the one partially efficacious HIV-1 vaccine. To build upon this discovery, we experimentally and computationally evaluated humoral responses to define envelope glycoproteins representative of the antigenic diversity of HIV globally. These diverse envelope antigens distinguished binding antibody breadth and durability among vaccine candidates, thus providing insights for advancing the most promising HIV-1 vaccine candidates.

Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity

B Cell Responses to HIV-1 Infection and Vaccination: Pathways to Preventing Infection

Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cells

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.

Affinity Maturation In An Hiv Broadly Neutralizing B-Cell Lineage Through Reorientation Of Variable Domains

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

HIV-1 Antibodies from Infection and Vaccination: Insights for Guiding Vaccine Design

Initiation of HIV Neutralizing B Cell Lineages with Sequential Envelope Immunizations

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Affinity gaps among B cells in germinal centers drive the selection of MPER precursors

Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Antibody‐virus Co‐evolution in HIV Infection: Paths for HIV Vaccine Development

E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Vaccination Induces Maturation of Diverse Unmutated VRC01-class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-humanized Mouse Model

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Antigen affinity and site of immunization dictate B cell recall responses

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies